Broadly neutralizing antibodies against HIV-1: templates for a vaccine

Virology. 2013 Jan 5;435(1):46-56. doi: 10.1016/j.virol.2012.10.004.

Abstract

The need for an effective vaccine to prevent the global spread of human immunodeficiency virus type 1 (HIV-1) is well recognized. Passive immunization and challenge studies in non-human primates testify that broadly neutralizing antibodies (BrNAbs) can accomplish protection against infection. In recent years, the introduction of new techniques has facilitated the discovery of an unprecedented number of new human BrNAbs that target and delineate diverse conserved epitopes on the envelope glycoprotein spike (Env). The epitopes of these BrNAbs can serve as templates for immunogen design aimed to induce similar antibodies. Here we will review the characteristics of the different classes of BrNAbs and their target epitopes, as well as factors associated with their development and implications for vaccine design.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS Vaccines / administration & dosage
  • AIDS Vaccines / immunology*
  • Animals
  • Antibodies, Neutralizing
  • Antigens, Viral / chemistry
  • Antigens, Viral / immunology*
  • HIV Antibodies / administration & dosage
  • HIV Antibodies / chemistry
  • HIV Antibodies / immunology*
  • HIV Infections / immunology
  • HIV Infections / prevention & control*
  • HIV Infections / virology
  • HIV-1 / immunology*
  • Humans
  • Immunity, Humoral
  • Immunization, Passive
  • Neutralization Tests
  • Protein Structure, Tertiary
  • env Gene Products, Human Immunodeficiency Virus / chemistry
  • env Gene Products, Human Immunodeficiency Virus / immunology*

Substances

  • AIDS Vaccines
  • Antibodies, Neutralizing
  • Antigens, Viral
  • HIV Antibodies
  • env Gene Products, Human Immunodeficiency Virus